GSK plc and Spero Therapeutics announced that the pivotal phase III PIVOT-PO trial evaluating tebipenem HBr ... at the test-of-cure visit. The IDMC review did not identify any new safety concerns ...

Specialties that saw increases in wait times since 2022 include gynecology (33%) dermatology (6%), cardiology (23%) and family medicine (14%). The average wait time for gastroenterology, which was ...

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

My review bike was set up with the cables routed internally through the Pivot Gravel Stem and Token C-Box headset, but it was shipped directly to me from Pivot, and I had given them my measurements ...

The National Law Review is not a law firm nor is www.NatLawReview.com intended to be a referral service for attorneys and/or other professionals. The NLR does not wish, nor does it intend ...

Many raised large amounts of venture capital on the back of expansive visions and aggressive customer acquisition, only to retreat, lay off staff, or pivot entirely as market conditions shifted. Wise ...

May 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics (SPRO), Inc. (Nasdaq: SPRO) and GSK plc (LSE/NYSE: GSK), today announced that the pivotal Phase 3 PIVOT-PO ... The IDMC review did not identify ...

May 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) and GSK plc (LSE/NYSE: GSK), today announced that the pivotal Phase 3 PIVOT-PO trial evaluating ... at the test-of-cure visit.